4'j piso wifi
2025-01-12   

None4'j piso wifi 。

From wealth and success to murder suspect

From wealth and success to murder suspect, the life of Luigi Mangione took a hard turn

Trade Finance Market Size, Share 2024, Impressive Industry Growth Report 2031GraniteShares 2x Long NVDA Daily ETF (NASDAQ:NVDL) Stock Price Down 2.4% – Here’s What HappenedFOX Business' Cheryl Casone joins 'Fox & Friends First' to discuss the backlash in response to Jaguar's 'woke' rebrand. FIRST ON FOX: Conservative watchdog group, America First Legal (AFL) launched a new initiative Thursday to help parents protect their children from what it describes as "woke leftist teachings in K-12 schools, colleges, and universities." "For the past four years, public schools have been indoctrinating children with radical racist, antisemitic, and transgender ideologies," Ian Prior, AFL's senior advisor said in a statement. "As these schools have blatantly violated civil rights law, the Biden Administration worked hand in glove to federalize the illegal practices. That ends in 2025, as the incoming administration has made clear that it will crack down on these woke schools that abuse their federal funds to implement insane ideologies that hurt children." The newly unveiled "Parents’ Rights Toolkit" provides resources and guidance for families looking to challenge policies they believe are discriminatory or harmful, including those that involve race and gender issues, AFL said in a news release. DEMOCRATIC LAWMAKER RANTS ABOUT 'THE WHITE MAN’ DURING HEARING ON THE DISMANTLE DEI ACT Criticism over workplace DEI commitments was bolstered following last year's affirmative action ruling from the Supreme Court that barred racial preferences in university admissions. The toolkit offers template letters to help parents file complaints with the Department of Education’s Office for Civil Rights, addressing potential violations of civil rights protections under Title IX, Title VI, and the Protection of Pupil Rights Amendment (PPRA). AFL, which was founded by Stephen Miller and other former Trump administration officials, intends for the toolkit to also serve as a roadmap for action for the incoming Trump administration. JOHNSON BLASTS DEM ACCUSATIONS HE VOWED TO END OBAMACARE AS 'DISHONEST' The editor of Scientific American is no fan of President-elect Donald Trump. (AP Photo/Evan Vucci, File) "AFL’s toolkit was created to help parents speak up for civil rights," AFL's news release said. "Now is the time for them to do — these claims will provide the incoming Trump administration with a critical roadmap for ending woke indoctrination and discrimination in our schools and colleges." CLICK HERE TO GET THE FOX NEWS APP The toolkit comes amid a conservative wave of pushback against DEI policies . At a House Oversight Committee hearing on Wednesday, the "Dismantle DEI Act" was under discussion, a session during which Rep. Jasmine Crockett, D-Texas, expressed her frustration. MIKE JOHNSON WINS REPUBLICAN SUPPORT TO BE HOUSE SPEAKER AGAIN AFTER TRUMP ENDORSEMENT Rep. Jasmine Crockett ranted about 'White men' while discussing a bill that seeks to remove DEI policies from the federal government. She concluded her remarks by claiming "companies with more diverse workforces are more likely to outperform their competitors." "Diversity works, and until you can show me data that says otherwise, I think that we need to go back to being a country that listens to experts and gets out of our feelings and recognizes again that racism is real in this country, and until we stop pretending that it's not, we will not solve the problems that we are consistently facing. And that will bring real unity that we seek when we're looking for a more perfect union," she said. Fox News Digital's Alexander Hall contributed to this report. Jamie Joseph is a writer who covers politics. She leads Fox News Digital coverage of the Senate.

outboundIQ Achieves Certified Implementation Partner (CIP) Status with Five9The Latest: UnitedHealthcare shooting suspect contests his extradition back to New YorkFiscalNote to Participate at Upcoming Investor Conferences

PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq. Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work. As part of this workforce reduction, Dr. Ahmed Hamdy, Chairman and Chief Executive Officer (CEO), has stepped down as CEO but will remain as Chairman. Dr. Raquel Izumi has stepped down as President and Chief Operations Officer and taken over as Acting CEO in a consulting capacity. Alexander Seelenberger has stepped down as Chief Financial Officer, and Kevin Hass, the Company’s Vice President and Controller, has taken over as Acting Chief Financial Officer. Mr. Seelenberger has agreed to provide ongoing assistance in a consulting capacity to assist the Company as it pursues its strategic efforts. “This strategic transaction highlights Vincerx’s commitment to develop ADCs with improved safety profiles that allow patients to thrive on—rather than endure—their cancer therapies,” said Raquel Izumi, Ph.D., Acting Chief Executive Officer. “Oqory’s anti-TROP2 ADC has shown favorable efficacy and safety in the clinic. Among approximately 150 treated patients, results include an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer (TNBC; n=30). Unlike other TROP2 ADCs in Phase 3, no cases of interstitial lung disease or Grade 3 and above stomatitis have been reported. Oqory’s Phase 3 studies of OQY-3258 are ongoing to confirm these promising findings.” About OQY-3258 (also known as ESG401) OQY-3258 is Oqory’s anti-TROP2 ADC with an optimized enzyme-dependent linker technology and an SN-38 payload with established efficacy and manageable side effect profile. OQY-3258 has completed Phase 1/2 development in over 150 patients with solid tumors, including metastatic HR+/HER2- and triple-negative breast cancer. OQY-3258 has shown efficacy in these patients, including reduction of brain metastasis and responses in heavily pretreated patients. To date, OQY-3258 has exhibited a differentiated safety profile vs. Trodelvy and other TROP2 ADCs in Phase 3 development. Notably, no interstitial lung disease or ocular surface events have been observed. Gastrointestinal effects have been mild and mainly Grade 1/2. Neutropenia and leukopenia have been the major AEs, which were manageable and did not result in discontinuation of study drug. OQY-3258 is being evaluated in a Phase 3 study as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer ( NCT06732323 ) and in a Phase 3 study in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer ( NCT06383767 ). About Oqory, Inc. Oqory, Inc. is an innovator in the field of ADCs with expertise in advancing targeted cancer therapies. The Company’s pipeline includes multiple ADC programs, with two currently in clinical development and several next-generation ADCs in preclinical stages. These programs are designed to address critical unmet needs in indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, multiple myeloma, and other metastatic solid tumors. Powered by a proprietary ADC platform, Oqory is delivering therapies that have demonstrated promising efficacy and safety paving the way for improved patient outcomes. About Vincerx Pharma, Inc. Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which has completed a Phase 1 monotherapy study; a preclinical ADC, VIP924; and VersAptxTM, a versatile, next-generation bioconjugation platform. Vincerx is based in Palo Alto, California, and has a research subsidiary in Monheim, Germany. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “suggest,” “seek,” “intend,” “plan,” “goal,” “potential,” “on-target,” “on track,” “project,” “estimate,” “anticipate,” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, the entry into a definitive merger agreement; the anticipated terms and closing of the merger, the $20 million equity investment, and the amount and timing of the interim financing; the expected ownership structure and value to Vincerx stockholders upon closing of the merger; the anticipated benefits of a merger transaction; and the clinical results of Oqory’s product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations, and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside Vincerx’s control. Actual results, conditions, and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions, and events to differ materially from those indicated in the forward-looking statements include, but are not limited to, Vincerx’s capital requirements, availability and sufficiency of capital, and cash runway; the ability of the parties to enter into a definitive merger agreement and the final terms thereof; the parties’ ability to satisfy the conditions precedent to the merger, including stockholder approval; the closing of the merger; the risk that any definitive agreement is terminated after it is entered into but before consummation of any proposed merger;; Vincerx’s reliance on receipt of interim funding; market acceptance of the combined company; risks associated with clinical development of the Vincerx and Oqory product candidates; general economic, financial, legal, political, and business conditions; and the risks and uncertainties set forth in Vincerx’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and subsequent reports filed with the Securities and Exchange Commission by Vincerx. Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements. Vincerx and the Vincerx logo are trademarks of Vincerx. This press release also contains trademarks and trade names that are the property of their respective owners. Contacts: Gabriela Jairala Vincerx Pharma, Inc. gabriela.jairala@vincerx.com Totyana Simien Inizio Evoke Comms totyana.simien@inizioevoke.comThe Importance of Genetic Testing in Modern Cannabis Seed Banks

City at least avoided a sixth consecutive defeat but the manner in which they blew a commanding advantage will do little to settle nerves in and around the club ahead of Sunday’s trip to Premier League leaders Liverpool. City appeared in total control after a brace from Erling Haaland and another from Ilkay Gundogan had them three up seven minutes into the second half, but after Anis Hadj Moussa got one back in the 75th minute, City imploded. “It is what it is, difficult to swallow right now,” Guardiola said. “The game was good, we played well, we scored three and could have scored more. We do everything and then we give away, especially the first one, and after we are not stable enough to do it. “It’s not about no run or no commitment, but football you have to be [switched on] in certain moments to do it.” Santiago Gimenez got Feyenoord’s second in the 82nd minute and David Hancko got a dramatic equaliser in the 89th, making City the first team in Champions League history to have led 3-0 in the 75th minute of a match and fail to win. Some City fans, who suffered through Saturday’s 4-0 humiliation at home to Tottenham, made their frustrations known at the final whistle. “The last game against Tottenham, 0-4, the supporters were there, applause,” he said. “They are disappointed of course and we understand it. “People come here not to remember success of the past, they come here to see the team win and perform well. I am not the one when the situation is bad or good [to say] what they have to do. “These supporters, when we go away, our fans are amazing, travelling. There is nothing to do and they are right to express what they feel.” Guardiola’s own frustrations were apparent given the number of scratches visible on his head after the match. The Catalan had arrived at the ground with a cut on his nose, which he said he had caused himself with a long fingernail. City now face a trip to Anfield to face the Liverpool side of former Feyenoord boss Arne Slot, whose named was chanted by the visiting fans during the match. “Everybody knows the situation, I don’t have to add absolutely anything,” Guardiola said. “We are going to train tomorrow, recovery and prepare the next game. Day off and we have two or three days to prepare that and go for it. We will learn for the future and what has been has been. “It will be a tough season for us and we have to accept it for many circumstances.” Feyenoord’s late fightback brought jubilant scenes in the away end. “I think if you’re from Feyenoord it was an unbelievable evening,” head coach Brian Priske said. “A strange game which ends 3-3 which is an unbelievable result for us and also remarkable in the essence of being 3-0 down in minute 75 away from home against still, for me, the best team in the world. “Normally we don’t celebrate draws but this one is a little bit special.”US President-elect Donald Trump filed a brief Friday urging the Supreme Court to pause a law that would ban TikTok the day before his January 20 inauguration if it is not sold by its Chinese owner ByteDance. "In light of the novelty and difficulty of this case, the court should consider staying the statutory deadline to grant more breathing space to address these issues," Trump's legal team wrote, to give him "the opportunity to pursue a political resolution." Trump was fiercely opposed to TikTok during his 2017-21 first term, and tried in vain to ban the video app on national security grounds. The Republican voiced concerns -- echoed by political rivals -- that the Chinese government might tap into US TikTok users' data or manipulate what they see on the platform. US officials had also voiced alarm over the popularity of the video-sharing app with young people, alleging that its parent company is subservient to Beijing and that the app is used to spread propaganda, claims denied by the company and the Chinese government. Trump called for a US company to buy TikTok, with the government sharing in the sale price, and his successor Joe Biden went one stage further -- signing a law to ban the app for the same reasons. Trump has now, however, reversed course. "Now (that) I'm thinking about it, I'm for TikTok, because you need competition," he recently told Bloomberg. More from this section "If you don't have TikTok, you have Facebook and Instagram -- and that's, you know, that's Zuckerberg." Facebook, founded by Mark Zuckerberg and part of his Meta tech empire, was among the social media networks that banned Trump after attacks by his supporters on the US Capitol on January 6, 2021. The ban was driven by concerns that he would use the platform to promote more violence. Those bans on major social media platforms were later lifted. In the brief filed on Friday, Trump's lawyer made it clear the president-elect did not take a position on the legal merits of the current case. "President Trump takes no position on the underlying merits of this dispute," John Sauer wrote in the amicus curiae -- or "friend of the court" -- brief. "Instead, he respectfully requests that the court consider staying the act's deadline for divestment of January 19, 2025, while it considers the merits of this case, thus permitting President Trump's incoming Administration the opportunity to pursue a political resolution of the questions at issue in the case." ft/ahaPITTSBURGH, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Center for Vein Restoration has recently announced that it suffered from a cybersecurity attack that impacted the personal information of over 446,000 of its patients and employees. The information potentially impacted in the breach includes names, addresses, dates of birth, Social Security numbers, driver’s license numbers, medical record numbers, medical information, health insurance information, financial information, and employment information. Lynch Carpenter, LLP is investigating claims against Center for Vein Restoration related to this data breach. If you’ve received a data breach notification from Center for Vein Restoration, you may be entitled to compensation. If you have received a notification from Center for Vein Restoration, that your information was impacted, please call Patrick Donathen at (412) 322-9243, email him at patrick@lcllp.com , or fill out our contact form at www.lynchcarpenter.com/contact . About Lynch Carpenter Lynch Carpenter is a national class action law firm with offices in Pennsylvania, California, and Illinois. Our firm has represented millions of clients in data privacy matters for more than a decade and has earned national acclaim for complex litigation for plaintiffs across the country. To learn more, please visit www.lynchcarpenter.com . CONTACT Patrick Donathen COMPANY Lynch Carpenter LLP PHONE (412) 322-9243 EMAIL patrick@lcllp.com WEB lynchcarpenter.com

Kungiyar tsofaffin yan sanda ta yi barazanar yajin aikin cin abinciJ.K. Dobbins' knee injury could be tough news for the Chargers offense

Clear Blue Technologies Announces Shares for Debt Settlement, Private Placement, and Proposed Share ConsolidationWho are the favorites to win Golden Globes? | Streamed & Screened podcastPep Guardiola called Manchester City’s 3-3 draw with Feyenoord “difficult to swallow” and admitted he understood the boos that greeted the final whistle after his side threw away a 3-0 lead in the last 15 minutes. City at least avoided a sixth consecutive defeat but the manner in which they blew a commanding advantage will do little to settle nerves in and around the club ahead of Sunday’s trip to Premier League leaders Liverpool. City appeared in total control after a brace from Erling Haaland and another from Ilkay Gundogan had them three up seven minutes into the second half, but after Anis Hadj Moussa got one back in the 75th minute, City imploded. “It is what it is, difficult to swallow right now,” Guardiola said. “The game was good, we played well, we scored three and could have scored more. We do everything and then we give away, especially the first one, and after we are not stable enough to do it. “It’s not about no run or no commitment, but football you have to be [switched on] in certain moments to do it.” Santiago Gimenez got Feyenoord’s second in the 82nd minute and David Hancko got a dramatic equaliser in the 89th, making City the first team in Champions League history to have led 3-0 in the 75th minute of a match and fail to win. Some City fans, who suffered through Saturday’s 4-0 humiliation at home to Tottenham, made their frustrations known at the final whistle. “The last game against Tottenham, 0-4, the supporters were there, applause,” he said. “They are disappointed of course and we understand it. “People come here not to remember success of the past, they come here to see the team win and perform well. I am not the one when the situation is bad or good [to say] what they have to do. “These supporters, when we go away, our fans are amazing, travelling. There is nothing to do and they are right to express what they feel.” Guardiola’s own frustrations were apparent given the number of scratches visible on his head after the match. The Catalan had arrived at the ground with a cut on his nose, which he said he had caused himself with a long fingernail. City now face a trip to Anfield to face the Liverpool side of former Feyenoord boss Arne Slot, whose named was chanted by the visiting fans during the match. “Everybody knows the situation, I don’t have to add absolutely anything,” Guardiola said. “We are going to train tomorrow, recovery and prepare the next game. Day off and we have two or three days to prepare that and go for it. We will learn for the future and what has been has been. “It will be a tough season for us and we have to accept it for many circumstances.” Feyenoord’s late fightback brought jubilant scenes in the away end. “I think if you’re from Feyenoord it was an unbelievable evening,” head coach Brian Priske said. “A strange game which ends 3-3 which is an unbelievable result for us and also remarkable in the essence of being 3-0 down in minute 75 away from home against still, for me, the best team in the world. “Normally we don’t celebrate draws but this one is a little bit special.”

New treatment reverses cancer by converting tumour cells into healthy cellsHoliday shopping doesn't have to be stressful

Barry Odom begins Purdue career with larger NIL budget and questions about payment dispute at UNLV

Related hot word search:

Previous: 3 j's hardware
Next: a bet casino